Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the target of a significant drop in short interest in October. As of October 30th, there was short interest totaling 9,125 shares, a drop of 49.8% from the October 15th total of 18,161 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,875 shares, the days-to-cover ratio is presently 1.0 days.
Ascentage Pharma Group International Stock Performance
Shares of AAPG opened at $14.62 on Monday. Ascentage Pharma Group International has a 12-month low of $13.46 and a 12-month high of $34.50. The business has a 50-day simple moving average of $15.36 and a two-hundred day simple moving average of $19.61. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. As a group, analysts predict that Ascentage Pharma Group International will post -2.43 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on Ascentage Pharma Group International
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
See Also
- Five stocks we like better than Ascentage Pharma Group International
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
